Amy Manning-Bog

4.3k citations

29 papers · 3.2k indexed · 2 hit papers · h-index 19

Neurology top 0.5%
Cellular and Molecular Neuroscience top 2%
Physiology top 2%
Molecular Biology top 10%
Neurology top 2%

Co-authors: Donato A. Di Monte Alison L. McCormack J. William Langston Anthony L. Fink Vladimir N. Uversky Deborah A. Cory‐Slechta Mona Thiruchelvam Christine Thiffault
Topics: Parkinson's Disease Mechanisms and Treatments (17 papers)Nerve injury and regeneration (5 papers)Lysosomal Storage Disorders Research (5 papers)
Cited by: Neurology Cellular and Molecular Neuroscience
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Journal of Clinical Oncology
Partner nations: United States Italy Germany

In The Last Decade

Amy Manning-Bog

27 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat

2002 602 citations Alison L. McCormack, Mona Thiruchelvam et al. Neurobiology of Disease profile →
The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Mice

2002 507 citations Amy Manning-Bog, Alison L. McCormack et al. Journal of Biological Chemistry profile →

Peers

Countries citing papers authored by Amy Manning-Bog

Since Specialization

Citations

This map shows the geographic impact of Amy Manning-Bog's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Manning-Bog with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Manning-Bog more than expected).

Fields of papers citing papers by Amy Manning-Bog

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Manning-Bog. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Manning-Bog. The network helps show where Amy Manning-Bog may publish in the future.

Co-authorship network of co-authors of Amy Manning-Bog

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Manning-Bog. A scholar is included among the top collaborators of Amy Manning-Bog based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Manning-Bog. Amy Manning-Bog is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-human phase Ib study of ATRC-101, an engineered version of a patient-derived antibody targeting a tumor-restricted ribonucleoprotein complex. 2020 ·Journal of Clinical Oncology ·Jonathan Benjamin,Nicholas Higgins,Carl Millward,Jeff DeFalco,Amy Manning-Bog,Iraz T. Aydin,Danhui Zhang,Shaun M. Lippow,Alexander Scholz,Yvonne Leung,Yanhong Zhu,(unknown),(unknown),(unknown),Daniel Emerling,William H. Robinson,Tito Serafini,Norman M. Greenberg	0
2	Axonal transport of AAV9 in nonhuman primate brain 2016 ·Gene Therapy ·(unknown),Lluı́s Samaranch,(unknown),Amy Manning-Bog,Kathrin Meyer,John Forsayeth,Krystof S. Bankiewicz	41
3	Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer’s disease model mice 2016 ·Brain ·Nathaniel S. Woodling,Damien Colas,Qian Wang,Paras S. Minhas,(unknown),Xibin Liang,Siddhita D. Mhatre,Holden D. Brown,(unknown),Irène Zagol-Ikapitte,Marieke van der Hart,Taline V. Khroyan,Bayarsaikhan Chuluun,(unknown),Ginger L. Milne,Arash Rassoulpour,Olivier Boutaud,Amy Manning-Bog,H. Craig Heller,Katrin I. Andreasson	78
4	Anti-Inflammatory and Neuroprotective Effects of PGE2 EP4 Signaling in Models of Parkinson’s Disease 2016 ·Journal of Neuroimmune Pharmacology ·Suraj Pradhan,(unknown),(unknown),Jenny U. Johansson,Qian Wang,Amy Manning-Bog,Katrin I. Andreasson	27
5	Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease 2014 ·Journal of Visualized Experiments ·Vivian Chou,(unknown),Theodore R. Holman,Amy Manning-Bog	10
6	Associations between in vivo neuroimaging and postmortem brain cytokine markers in a rodent model of Wernicke's encephalopathy 2014 ·Experimental Neurology ·Natalie M. Zahr,Carsten Alt,Dirk Mayer,Torsten Rohlfing,Amy Manning-Bog,Richard Luong,Edith V. Sullivan,Adolf Pfefferbaum	17
7	Suppression of Inflammation with Conditional Deletion of the Prostaglandin E₂EP2 Receptor in Macrophages and Brain Microglia 2013 ·Journal of Neuroscience ·Jenny U. Johansson,Suraj Pradhan,(unknown),Nathaniel S. Woodling,(unknown),Holden D. Brown,Qian Wang,Christina Loh,Egle Cekanaviciute,Marion S. Buckwalter,Amy Manning-Bog,Katrin I. Andreasson	74
8	Evidence of oxidative stress in young and aged DJ‐1‐deficient mice 2013 ·FEBS Letters ·Arjun V. Raman,Vivian Chou,(unknown),Donato A. Di Monte,Frederick P. Bellinger,Amy Manning-Bog	14
9	Differential contribution of lipoxygenase isozymes to nigrostriatal vulnerability 2012 ·Neuroscience ·Vivian Chou,Theodore R. Holman,Amy Manning-Bog	21
10	Glutathione Peroxidase 4 is associated with Neuromelanin in Substantia Nigra and Dystrophic Axons in Putamen of Parkinson's brain 2011 ·Molecular Neurodegeneration ·Frederick P. Bellinger,Miyoko T. Bellinger,Lucia A. Seale,(unknown),Arjun V. Raman,Takanori Miki,Amy Manning-Bog,Marla J. Berry,Lon R. White,George Ross	139
11	Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease 2011 ·Toxicology Letters ·Mikhail S. Shchepinov,Vivian Chou,Erik D. Pollock,J. William Langston,Charles R. Cantor,(unknown),Amy Manning-Bog	58
12	Lysosomal Degradation of α-Synuclein in Vivo 2010 ·Journal of Biological Chemistry ·Sally K. Mak,Alison L. McCormack,Amy Manning-Bog,Ana María Cuervo,Donato A. Di Monte	278
13	Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: A biological link between Gaucher disease and parkinsonism 2009 ·NeuroToxicology ·Amy Manning-Bog,Birgitt Schüle,J. William Langston	150
14	Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter 2007 ·Neurobiology of Disease ·Amy Manning-Bog,W. Michael Caudle,Xiomara A. Perez,Stephen H. Reaney,Ronald F. Paletzki,(unknown),Vivian Chou,Alison L. McCormack,Gary W. Miller,J. William Langston,Charles R. Gerfen,Donato A. Di Monte	74
15	Model fusion: The next phase in developing animal models for parkinson’s disease 2007 ·Neurotoxicity Research ·Amy Manning-Bog,J. William Langston	48
16	Nuclear Localization of α-Synuclein and Its Interaction with Histones 2003 ·Biochemistry ·John Goers,Amy Manning-Bog,Alison L. McCormack,Ian S. Millett,Sebastian Doniach,Donato A. Di Monte,Vladimir N. Uversky,Anthony L. Fink	264
17	Environmental Factors in Parkinson’s Disease 2002 ·NeuroToxicology ·Donato A. Di Monte,Mitra Lavasani,Amy Manning-Bog	179
18	Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquatbreakdown → 2002 ·Neurobiology of Disease ·Alison L. McCormack,Mona Thiruchelvam,Amy Manning-Bog,Christine Thiffault,J. William Langston,Deborah A. Cory‐Slechta,Donato A. Di Monte	602
19	The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Micebreakdown → 2002 ·Journal of Biological Chemistry ·Amy Manning-Bog,Alison L. McCormack,Jie Li,Vladimir N. Uversky,Anthony L. Fink,Donato A. Di Monte	507
20	Decreased expression of the transcription factor NURR1 in dopamine neurons of cocaine abusers 2002 ·Proceedings of the National Academy of Sciences ·Michael J. Bannon,(unknown),Amy Manning-Bog,C. W. M. Whitty,Sharon K. Michelhaugh,Paola Sacchetti,James G. Granneman,Deborah C. Mash,Carl J. Schmidt	78

About Amy Manning-Bog

Amy Manning-Bog is a scholar working on Neurology, Neurology and Cellular and Molecular Neuroscience, having authored 29 papers that have together received 3.2k indexed citations. Recurring topics across this work include Parkinson's Disease Mechanisms and Treatments (17 papers), Nerve injury and regeneration (5 papers) and Lysosomal Storage Disorders Research (5 papers). The work is most often cited by research in Neurology (1.9k citations), Neurology (494 citations) and Cellular and Molecular Neuroscience (1.0k citations). Amy Manning-Bog has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Donato A. Di Monte, Alison L. McCormack, J. William Langston, Anthony L. Fink, Vladimir N. Uversky, Deborah A. Cory‐Slechta, Mona Thiruchelvam, Christine Thiffault, Jie Li and Sally K. Mak. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact